Product Description: Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively[1].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Wang Q, et al. A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host Microbe. 2020 Aug 12;28(2):335-349.e6.
CAS Number: 569658-79-3
Molecular Weight: N/A
Research Area: Infection
Solubility: 10 mM in DMSO
Target: HBV